NLRP3 and stroke disorder: RP‐1127, an intravenous formulation of the NLRP3 inflammasome inhibitor glyburide (Lamkanfi et al, 2009), is being tested in a clinical trial for stroke (EudraCT 2017‐004854‐41) after a positively evaluated pilot study (ClinicalTrials.gov: NCT01268683) (Sheth et al, 2014).